SCHEMBL1890331

SCHEMBL1890331

N#Cc1cc(F)cc(C(F)F)c1

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
EPAS1 Q99814 3/20 0.38
VEGFA P15692 2/20 0.36
GRM5 P41594 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29639654 1.00 EPAS1 (0.38) EPAS1VEGFAGRM5CYP11B1CYP11B2
SCHEMBL1890750 0.86 VCAM1 (0.38) EPAS1CYP11B1CYP11B2
SCHEMBL23564081 0.81 GRM5 (0.35) GRM5
SCHEMBL12262985 0.81 GRM5 (0.41) GRM5
SCHEMBL1421650 0.78 GRM5 (0.47) GRM5
SCHEMBL56741 0.78 GRM5 (0.43) GRM5
SCHEMBL29945798 0.78 GRM5 (0.36) GRM5
SCHEMBL23525975 0.78 GRM5 (0.36) GRM5
SCHEMBL16958513 0.78 GRM5 (0.36) EPAS1GRM5
SCHEMBL23525972 0.78 GRM5 (0.36) GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12610949-B2 Heteroaryl-triazole compounds as pesticides BAYER AKTIENGESELLSCHAFT (DE) 2026-04-28 US disclosed
CN-114502545-B Novel heteroaryl-triazole compounds as pesticides 拜耳公司 2024-06-28 CN disclosed
US-20230065953-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2023-03-02 US disclosed
EP-4065577-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES Bayer Aktiengesellschaft (DE) 2022-10-05 EP disclosed
US-20220264880-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2022-08-25 US disclosed
CN-114761402-A Novel heteroaryl-triazole compounds as pesticides 拜耳公司 2022-07-15 CN disclosed
EP-4003974-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES Bayer Aktiengesellschaft (DE) 2022-06-01 EP disclosed
CN-114502545-A Novel heteroaryl-triazole compounds as pesticides 拜耳公司 2022-05-13 CN disclosed
WO-2021105091-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2021-06-03 WO disclosed
WO-2021105091-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2021-06-03 WO disclosed
EP-1773790-A1 BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-04-18 EP disclosed
CN-1946680-A Non-nucleoside reverse transcriptase inhibitors HOFFMANN LA ROCHE (CH) 2007-04-11 CN disclosed
US-7166738-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-01-23 US disclosed
US-7166738-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-01-23 US disclosed
EP-1742908-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-01-17 EP disclosed
US-20060025462-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-02-02 US disclosed
WO-2006010545-A1 BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-02-02 WO disclosed
WO-2005102989-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-03 WO disclosed
US-20050239881-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2005-10-27 US disclosed
US-20050239880-A1 Methods for treating retroviral infections ROCHE PALO ALTO LLC 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12610949-B2 Heteroaryl-triazole compounds as pesticides CTRL, PTMS, DDT EPAS1 3923/4885VEGFA 3200/4885GRM5 516/4885
US-20230065953-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES GLRX3, TARS2, CYP4F3 EPAS1 4091/4885VEGFA 4361/4885GRM5 527/4885
US-20050239880-A1 Methods for treating retroviral infections CCR5, CD38, CD4 EPAS1 3126/4885VEGFA 4054/4885GRM5 1888/4885
US-20060025462-A1 Heterocyclic antiviral compounds MAVS, IRF3, ZC3HAV1 EPAS1 2739/4885VEGFA 1803/4885GRM5 3280/4885
US-20220264880-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES CYP4F3, TARS2, CAT EPAS1 4076/4885VEGFA 4299/4885GRM5 415/4885
US-20050239881-A1 Non-nucleoside reverse transcriptase inhibitors RPP30, PNP, RTF1 EPAS1 4373/4885VEGFA 3956/4885GRM5 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.